Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | TEK | Q02763 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333063 | 0.88 | NT5E (0.50) | NT5EGRK5KDRTEKP2RX7 | |
| SCHEMBL16331371 | 0.86 | GRK5 (0.50) | NT5EGRK5KDRPIM1KDM4E | |
| SCHEMBL16331090 | 0.81 | NT5E (0.48) | NT5EGRK5PIM1KDM4EHSD17B10 | |
| SCHEMBL16331202 | 0.80 | NT5E (0.48) | NT5EGRK5KDRPIM1KDM4E | |
| SCHEMBL16331071 | 0.78 | NT5E (0.59) | NT5EGRK5P2RX7NPY5RKDM4E | |
| SCHEMBL16331200 | 0.78 | NT5E (0.76) | NT5EGRK5PIM1KDM4EHSD17B10 | |
| SCHEMBL16331378 | 0.78 | GRK5 (0.62) | NT5EGRK5KDM4EHSD17B10MAPK14 | |
| SCHEMBL10960250 | 0.77 | GRK5 (0.61) | NT5EGRK5KDRTEKPIM1 | |
| SCHEMBL14653628 | 0.76 | PIM1 (0.50) | NT5EPIM1KDM4EHSD17B10NPC1 | |
| SCHEMBL31541590 | 0.76 | TRPA1 (0.52) | NT5EPIM1KDM4EHSD17B10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | NT5E 2132/4885GRK5 3/4885KDR 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.